Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-2393

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-2393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2393 3)

Label for Venlafaxine Hydrochloride 37.5 mg extended-release capsules by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 capsules, Rx only, with storage instructions and a warning to keep out of reach of children. Manufacturer is Amnora Pharma Pvt. Ltd., Telangana, India. The NDC is 68071-2393-3.*

FDA Label Image

Figure1 (Figure1)

A chart depicting pharmacokinetic fold changes and 90% confidence intervals for venlafaxine hydrochloride when interacting with various drugs, including ethanol, diazepam, cimetidine, ketoconazole (CYP2D6 EMs and PMs), indinavir, metoprolol, imipramine, and lithium. The graph shows changes relative to a reference value, organized by analyte parameters such as Cmax, AUC, and ODV, along with recommended clinical considerations for each interaction.*

FDA Label Image

Figure2 (Figure2)

A forest plot chart illustrating pharmacokinetic fold changes with 90% confidence intervals for various interacting drugs with Venlafaxine Hydrochloride. The chart lists analytes like ethanol, diazepam, alprazolam, and others, showing Cmax and AUC values relative to a reference value, alongside recommendations such as dose adjustments or monitoring requirements.*

FDA Label Image

Figure3 (Figure3)

A dot plot chart showing pharmacokinetic fold changes and 90% confidence intervals of venlafaxine and its metabolite ODV in special populations, including hepatic and renal impairments, CYP2D6 metabolizer status, age over 60, and gender. The x-axis represents change relative to a reference value, and recommendations for dose adjustments are noted for specific populations.*

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Logo2 (Logo2)

FDA Label Image

Venlafaxinestructure (Venlafaxinestructure)

Chemical structure of Venlafaxine Hydrochloride showing its molecular arrangement with a chiral center indicated in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.